Paige

Paige.ai is an artificial intelligence company dedicated to transforming cancer diagnostics and pathology through next-generation AI technology. Now a Tempus company, Paige was among the first organizations to apply foundation models to cancer care, and has since developed a comprehensive suite of AI-powered solutions that set new standards for size, scale, and performance in computational pathology. Paige serves pathologists, healthcare institutions, research organizations, and biopharma partners across more than 45 countries, with its technology trusted by over 800 laboratory and medical institutions worldwide.

At the core of Paige's mission is a commitment to solving cancer's most critical diagnostic challenges. The company leverages exclusive access to one of the largest and most diverse digital pathology datasets available — encompassing 25 million accessible pathology slides, data from 350,000 patients, and 200,000 cases with outcome and genomic data — to deliver AI that provides a holistic, precise understanding of cancer across more than 40 cancer types and a broad spectrum of gender, race, ethnicity, and geographical regions.

AI-Assisted Diagnostic and Biomarker Applications

• Paige Prostate Suite: A comprehensive group of AI applications that aid in the detection and diagnosis of prostate cancer on H&E-stained whole-slide images of prostate needle biopsies.
• Paige Breast Suite: A set of AI applications designed to support pathologists in the identification and classification of breast cancer on H&E-stained whole-slide images from breast biopsy and excision specimens.
• Paige GI Suite: A powerful portfolio of AI-powered applications supporting pathologists in the detection and classification of benign and malignant conditions across the entire gastrointestinal tract, built on Paige's latest foundation model technology.
• Paige PanCancer Suite: Developed using the Virchow foundation model and trained on over 1.5 million slides, this suite helps pathologists identify subtle complexities of cancer across multiple tissue types, including rare cancers.

These diagnostic applications are designed to alleviate time and resource pressures on pathologists, enabling them to better manage growing workloads while delivering informed, high-quality diagnoses. In addition to cancer detection and subtyping, Paige's AI technologies can reveal multiple molecular biomarkers directly from tissue samples.

AI Technology and Foundation Models

• Foundation Models: Paige offers a family of proprietary foundation models — including Virchow, Virchow2, Virchow2G, Virchow2G-Mini, and PRISM — that eliminate the need for task-specific training and can be licensed by third-party partners to develop customized AI models adhering to the highest standards of privacy, security, and clinical excellence.
• PanCancer AI Modules: Pre-built pan-cancer modules that enable precise therapeutic targeting, novel biomarker identification, and optimized clinical trial design.
• AI Development Services: Paige provides comprehensive services including AI and industry-specific expertise, custom AI development (such as prognostic or predictive applications), regulatory strategy, and commercialization services to help partners navigate regulatory hurdles and bring cutting-edge technology to market efficiently.

Paige Alba™

• Paige Alba is a proprietary multi-modal co-pilot designed to revolutionize pathology workflows and unlock precision medicine.
• Alba integrates cutting-edge AI with intuitive voice and text commands, enabling pathologists to streamline cancer detection and diagnosis processes and improve overall efficiency.
• Built on Paige's industry-leading diagnostic, biomarker, and foundation model technologies, Alba provides real-time insights and optimized workflows that empower clinicians.
• Alba is positioned as a clinical-grade solution aimed at advancing personalized medicine and precision oncology.

Data Diversity and Institutional Reach

• AI models trained to encompass a broad spectrum of gender, race, ethnicity, and geographical regions.
• Coverage of more than 40 cancer types.
• Partnerships with over 800 laboratory and medical institutions.
• Representation across more than 45 countries.
• Access to 25 million pathology slides, data from 350,000 patients, and 200,000 cases with outcome and genomic data.

Paige is funded and trusted by the industry's most influential investors, and has gained recognition from leading news organizations for its innovation in AI-driven cancer care. By combining world-class AI expertise with insights from renowned medical and scientific experts, Paige continues to push the boundaries of what is possible in precision diagnostics and computational pathology.